Rallybio price target lowered to $9 from $12 at H.C. Wainwright

H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Rallybio to $9 from $12 and keeps a Buy rating on the shares following the Q4 report. Given the seriousness of the consequences of treating a pregnant mother, it is possible that it could take longer than anticipated to convince expecting mothers to undergo treatment with an experimental therapy that affects the mom and fetus, the analyst tells investors in a research note. The firm pushed back its anticipated launch of RLYB212 to occur in 2027 versus 2026 previously.